2023 Quality Assurance Reporting Requirements (QARR)

August 28, 2023

RE: Clarification #2 for Measurement Year (MY)
2023 Updates

Dear Colleague,

This letter contains information about edits incorporated into the 2023 Quality Assurance Reporting Requirements (QARR) Technical Specifications, Patient Level Detail (PLD) for Measurement Year (MY)
2023 reporting, and Table 1- QARR List of Required Measures. The information contained in this clarification has been incorporated into a revised version of the QARR Technical Specifications for MY2023. The updated files are posted on our Managed Care Information for Health Plans page. The revised specifications should be used in the plans' processing for MY2023 QARR.

This clarification includes the following changes made to the 2023 QARR Technical Specifications Manual.

Change Version Version Date Section(s) Changed Change Summary
2 8/28/2023 QARR Technical Specifications
  • The recommended date to health plans to provide a draft version of the IDSS to their auditor, bullet #5 under Audit Requirements on page 10, has been updated to June 14, 2024.
     
  • The required reporting date of the Final Audit Report (FAR), page 12 in the Reporting Schedule table has been updated to July 14, 2024.
    Table 1 – QARR List of Required Measures
  • Colorectal Cancer Screening (COL) is required to be reported for Qualified Health Plans (QHP Table 1 - QARR List of Required Measures inadvertently had this notated as not required for reporting NR. This has been corrected to an (✓), Reporting Required MY2023.
     
  • Depression Remission or Response for Adolescents and Adults and Social Need Screening and Intervention (electronic versions) DSF-E & SNS-E are not required to be reported for Exchange product lines. Table 1 - QARR List of Required Measures inadvertently had this notated as required reporting (✓). This has been corrected to an NR.
     
  • Updated versions of the MY2023 Table 1: QARR List of Required Measures, that include the flags, product lines, reporting guidelines, and collection method key on all pages, have been posted to the NYS Managed Care website.
     
    Patient-Level Detail File (PLD) Commercial PLD:
  • Column Length Changed = 2 for Race
  • Column Length Changed = 2 for Source of Race Data
  • Source of Race Data field, valid values have been updated to align with NCQA/HEDIS specifications.
  • Column Length Changed = 2 for Source of Ethnicity Data
  • Source of Ethnicity Data field, valid values have been updated to align with NCQA/HEDIS specifications.
  • The Language Spoken field has been updated to include a link to Language Value Set on the NYS QARR Language Value Set webpage.
  • Column Start and Column End numbering was corrected.
      Medicaid PLD:
  • Column Length Changed = 2 for Race
  • Column Length Changed = 2 for Source of Race Data
  • Source of Race Data field, valid values have been updated to align with NCQA/HEDIS specifications.
  • Column Length Changed = 2 for Source of Ethnicity Data
  • Source of Ethnicity Data field, valid values have been updated to align with NCQA/HEDIS specifications.
  • Language Spoken field has been updated to include a link to Language Value Set on the NYS QARR Language Value Set webpage.
  • Column Start and Column End numbering was corrected.
      Exchange PLD:
  • Column Length Changed = 2 for Race
  • Column Length Changed = 2 for Source of Race Data
  • Source of Race Data field, valid values have been updated to align with NCQA/HEDIS specifications.
  • Column Length Changed = 2 for Source of Ethnicity Data
  • Source of Ethnicity Data field, valid values have been updated to align with NCQA/HEDIS specifications.
  • Language Spoken field has been updated to include a link to Language Value Set on the NYS QARR Language Value Set webpage.
  • Measure COL (non-electronic version):
  • Denominator and Numerator specifications have been added for all age-bands for this measure.
  • Measure COL (electronic version):
  • Denominator and Numerator specifications have been added for 46-49 age-band for this measure.
  • Depression Remission or Response for Adolescents and Adults and Social Need Screening and Intervention (electronic versions) DSF-E & SNS-E
  • Not required to be reported Exchange product lines.
  • Column Start and Column End numbering was corrected.
    NYS Measure Specifications COVID-19 Immunization Status Measure (CVS)
  • No Change for MY2023
  • In May of 2023, both the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) amended the Emergency Use Authorizations (EUAs) of the Pfizer-BioNTech and Moderna bivalent mRNA vaccines by authorizing only bivalent vaccines. The specifications for the NYS CVS measure will not be further updated for MY2023.
  • For MY2024, we anticipate updating/revising our current COVID-19 Immunization Status Measure to align with the changes adapted by both the CDC and FDA.

If there are any questions about the above edits, or if you find issues or have concerns with the 2023 Technical Specifications manual or the 2023 Value Set, please email nysqarr@health.ny.gov.

Sincerely,

Paloma Luisi, MPH
Director, Bureau of Quality Measurement & Evaluation
Center for Applied Research and Evaluation
Office of Quality and Patient Safety

CC:  R. Josberger
        B. Bandle